Reliance Capital gets revision in ratings for LT debt program

February 18th, 2019

Reliance Capital announced that Brickwork Ratings has revised rating to AA for long-term debt program, market linked debentures and subordinated debt of the Company, primarily due to delay in monetisingthe non-core investments.

0 thoughts on “Reliance Capital gets revision in ratings for LT debt program”

Post Comment

Comment

Full name

Email address

Mobile

Daily News

VIEW ALL

BSE NSE halt trading for 1st time in 12 years Circuit breaker limit explained

-March 13th, 2020

Yes Bank inward RTGS enabled to receive payments

-March 12th, 2020

Nifty 50 may slip below 10000 mark as WHO calls coronavirus a pandemic

-March 12th, 2020

Yes Bank enables inward IMPS NEFT transactions

-March 11th, 2020

COVID19 oil prices pulls down RILs refining chemical valuation by $7 billion

-March 11th, 2020

Jet Airways Committee of Creditors to meet on Thursday

-March 11th, 2020

Investor euphoria punctured as Maruti disappoints on operating performance

-January 29th, 2020

Sumitomo Indias MNC parentage will count if profitability improves

-January 29th, 2020

Sumitomo Indias MNC parentage will count if profitability improves

-January 29th, 2020

Stocks to Watch DHFL InterGlobe Aviation HDFC Godfrey Phillips Torrent Pharma

-January 28th, 2020

Jio largest in revenue customers base India Ratings

-January 28th, 2020

Axis Bank delivers on growth but trouble lingers on the bad loans front

-January 23rd, 2020

Asian Paints revenue growth dims in Q3 but profit margins stay bright

-January 23rd, 2020

HDFC AMC clocks a steady Q3 but the stock remains pricey

-January 23rd, 2020

Vodafone Idea stocks jumps 20% over SC relief

-January 22nd, 2020

ICICI Pru Lifes profitability metrics impress but biz growth yet to cut ice

-January 22nd, 2020

ITIs Rs 1600cr FPO to open on Friday

-January 21st, 2020

Reality check for Kotak Bank stock as growth slows and slippages rise

-January 21st, 2020

NSE promoted PXIL develops real time power market with PRATYAY

-January 21st, 2020

Why investors doubt the logic behind Biocon Biologics deal valuation

-January 7th, 2020